NOVOCART DISC is a biologic-device combination product (combination autologous disc chondrocyte and a self polymerizing hydrogel) being explored for treating degenerative disc disease of the lumbar spine.

NOVOCART DISC treatment consists of a two step procedure. In the first step, the biopsy would be taken during a discectomy procedure that removes the region of herniated disc. The disc chondrocytes would be isolated and expanded and suspended into a hydrogel for implantation. The final product would be injected through the annulus into the nucleus pulposus. Once in place, the disc chondrocytes may help regenerate tissue for a healthier disc.

The product is the subject of a Phase 2 trial within the European Union.